Expression mismatch repair Proteins in gastric carcinoma treated XELOX adjuvant chemotherapy
Main Article Content
Abstract
Microsatellite instability is caused by mismatch repair protein mutations (MMRP) (including
MLH1, MSH2, PMS2, MSH6) and is one of the most important prognostic factors being studied in
gastric carcinoma. This study was conducted to determine the rate of MMRP expression and assess
the relationship between MMRP expression and clinical features, histopathology, and survival. This
study analyzed data from 67 patients with gastric carcinoma of stage pT3, N (+), M0, who were
treated by resectable surgery and adjuvant chemotherapy with XELOX regimen. Mismatch repair
proteins were determined by i mmunohistochemistry staining. Any stainings resulted in absence
of four mismatch repair proteins was defined as deficiency mismatch repair (dMMR). The rate of
dMMR was 14.9% and dMMR was associated with female patients and age group of ≤ 60 years.
There was no correlation between dMMR and tumor location, tumor size, lymph node metastasis,
and pathology. In conclusion, patients with dMMR had improvement in disease - free survival (p
= 0,039) and also tended to improve overall survival (p = 0,073) compared to the pMMR group.
Article Details
Keywords
mismatch repair protein, i mmunohistochemistry, gastric carcinoma
References
2. Smyth EC, Wotherspoon A, Peckitt C, et al. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 2017;3 (9):1197 - 1203.
3. Dai D, Zhao X, Li X, et al. Association Between the Microsatellite Instability Status and the Efficacy of Postoperative Adjuvant Chemoradiotherapy in Patients With Gastric Cancer. Front Oncol. 2020;9:1452.
4. Tsai C - Y, Lin T - A, Huang S - C, et al. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer? - Autophagy Inhibition Matches the Mismatched. The Oncologist. 2020;25 (7):e1021 - e1030,
5. Kim SY, Choi YY, An JY, et al. The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses. Int J Cancer. 2015;137 (4):819 - 825.
6. An JY, Kim H, Cheong J - H, Hyung WJ, Kim H, Noh SH. Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. Int J Cancer. 2012;131 (2):505 - 511. 7. Zhang J, Ma W, Wu H, et al. Analysis of Homogeneous and Heterogeneous Factors for Bone Metastasis in Esophageal Cancer. Med Sci Monit Int Med J Exp Clin Res. 2019;25:9416 - 9425.
8. Karpińska - Kaczmarczyk K, Lewandowska M, Ławniczak M, Białek A, Urasińska E. Expression of Mismatch Repair Proteins in Early and Advanced Gastric Cancer in Poland. Med Sci Monit Int Med J Exp Clin Res. 2016;22:2886 - 2892.
9. Miceli R, An J, Di Bartolomeo M, et al. Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. Oncology. 2019;97 (1):38 - 43.
10, Choi YY, Kim H, Yang H - K, et al. Clinical impact of microsatellite instability in patients with stage II and III gastric cancer: Results from the CLASSIC trial. J Clin Oncol. 2017;35 (15_suppl):4022 - 4022. doi:10,1200/ JCO.2017.35.15_suppl.4022 11. Zhu L, Li Z, Wang Y, Zhang C, Liu Y, Qu X. Microsatellite instability and survival in gastric cancer: A systematic review and meta - analysis. Mol Clin Oncol. 2015;3 (3):699 - 705.
12. Theuer CP, Campbell BS, Peel DJ, et al. Microsatellite Instability in Japanese vs European American Patients With Gastric Cancer. Arch Surg. 2002;137 (8):960 - 966.
13. Hashimoto T, Kurokawa Y, Takahashi T, et al. Predictive value of MLH1 and PD - L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2019;22 (4):785 - 792.
14. Bae YS, Kim H, Noh SH, Kim H. Usefulness of I mmunohistochemistry for Microsatellite Instability Screening in Gastric Cancer. Gut Liver. 2015;9 (5):629 - 635.